Biosimilars Market Research Report – Segmented by Product Type (Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-Inflammatory Agents, and Others); By Therapeutic Application (Oncology, Autoimmune Diseases, Hematology Disorders, Infectious Diseases, Endocrine Disorders, and Others); By Distribution Channels ( Hospital Pharmacies, Speciality Clinics and Centers, Retail Pharmacies, Online Pharmacies, and Others); and Region - Size, Share, Growth Analysis | Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-857
Format:
Region: Global
Chapter 1. Biosimilars Market - Scope & Methodology
1.1 Market Segmentation
1.2 Assumptions
1.3 Research Methodology
1.4 Primary Sources
1.5 Secondary Sources
Chapter 2. Biosimilars Market - Executive Summary
2.1 Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2 Key Trends & Insights
2.3 COVID-19 Impact Analysis
2.3.1 Impact during 2023 – 2030
2.3.2 Impact on Supply – Demand
Chapter 3. Biosimilars Market - Competition Scenario
3.1 Market Share Analysis
3.2 Product Benchmarking
3.3 Competitive Strategy & Development Scenario
3.4 Competitive Pricing Analysis
3.5 Supplier - Distributor Analysis
Chapter 4. Biosimilars Market - Entry Scenario
4.1 Case Studies – Start-up/Thriving Companies
4.2 Regulatory Scenario - By Region
4.3 Customer Analysis
4.4 Porter's Five Force Model
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Powers of Customers
4.4.3 Threat of New Entrants
4.4.4 Rivalry among Existing Players
4.4.5 Threat of Substitutes
Chapter 5. Biosimilars Market - Landscape
5.1 Value Chain Analysis – Key Stakeholders Impact Analysis
5.2 Market Drivers
5.3 Market Restraints/Challenges
5.4 Market Opportunities
Chapter 6. Biosimilars Market - By Product Type
6.1 Monoclonal Antibodies
6.2 Recombinant Hormones
6.3 Immunomodulators
6.4 Anti-Inflammatory Agents
6.5 Others
Chapter 7. Biosimilars Market - By Therapeutic Application
7.1 Oncology
7.2 Autoimmune Diseases
7.3 Hematology Disorders
7.4 Infectious Diseases
7.5 Endocrine Disorders
7.6 Others
Chapter 8. Biosimilars Market - By Distribution Channel
8.1 Hospital Pharmacies
8.2 Speciality Clinics and Centers
8.3 Retail Pharmacies
8.4 Online Pharmacies
8.5 Others
Chapter 9. Biosimilars Market – By Region
9.1 North America
9.2 Europe
9.3 Asia-Pacific
9.4 Latin America
9.5 The Middle East
9.6 Africa
Chapter 10. Biosimilars Market – Key players
10.1 Pfizer Inc.
10.2 Novartis International AG (Sandoz)
10.3 Amgen Inc.
10.4 Celltrion Inc.
10.5 Biocon Ltd.
10.6 Teva Pharmaceutical Industries Ltd.
10.7 Samsung Bioepis Co., Ltd.
10.8 Mylan N.V.
10.9 Fresenius Kabi AG
Download Sample
Choose License Type
2850
5250
4500
1800
Frequently Asked Questions
The Global Biosimilars Market was estimated to be worth USD 29.98 Billion in 2023 and is anticipated to reach a value of USD 70.70 Billion by 2030, growing at a fast CAGR of 11.32% during the forecast period 2023-2030.
The global Biosimilars market is driven by factors such as cost savings, increasing demand for biologics, rising prevalence of chronic diseases and cancer, and supportive government initiatives.
Monoclonal Antibodies, Insulin, Growth Factors, Interferons, and Erythropoietin are segments under the Global Biosimilars Market by product type.
Europe dominates the market in Global Biosimilars Market.
Asia-Pacific is the fastest-growing region in the Global Biosimilars Market.
